Market Size of Global Argatroban Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Argatroban Market Analysis
The argatroban market is expected to register a CAGR of 3.5% over the forecast period, 2022-2027.
The COVID-19 pandemic caused disruptions in the supply chains and treatment protocols for pharmaceuticals around the world, which also influenced the global anticoagulant, specific to the argatroban market. It also delays the research and development of medications for illnesses other than COVID-19. But the rate of thrombosis among COVID-19 hospitalized patients was found to be comparatively high early in the COVID-19 pandemic. In January 2021, Thorax, an international journal from BMJ published that COVID-19 patients may experience mild thrombocytopenia, mildly extended prothrombin time, increased fibrinogen, and elevated D-dimer that may lead to thrombosis. Thus COVID-19 had a significant impact on the market. Furthermore, it is anticipated that the market under study will eventually reach its full potential because of vaccination campaigns and a decline in COVID-19 cases.
Argatroban is a medicine used to prevent blood clots and helps in the improvement of neurological symptoms (motor paralysis) and activities of daily life (walking, standing, maintaining a sitting position, diet) associated with acute cerebral thrombosis. It is also used in the treatment of chronic arterial occlusion (Buerger's disease and arteriosclerosis obliterans), also as prophylaxis and for the prevention of heparin-induced thrombocytopenia (HIT) type II. In October 2020, the American Society of Hematology published that prothrombotic adverse drug reaction known as heparin-induced thrombocytopenia (HIT) can be observed in 0.1% to 7% of patients using heparin products, depending on patient population and type of heparin used in the medication. Heparin is necessary during routine hemodialysis in order to prevent clotting in the extracorporeal circuit. So, the argatroban is used to prevent the HIT in the hemodialysis patients. The other driving factor of argatroban market is the increased prevalence of cerebral venous thrombosis that can be observed in patients with HIT. In March 2022, American Heart Association published that 1.6% of people with HIT develop cerebral venous thrombosis. Hence, the increase in the prevalence of cerebral venous thrombosis may increase the growth of the argatroban market.
However, the side effects and related allergies of argatroban treatment is expected to restrain growth in the argatroban market during the forecast period of the study.
